Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China-Biotics hits public offering target

This article was originally published in The Tan Sheet

Executive Summary

Probiotics manufacturer China-Biotics reports net proceeds of $65.5 million in its underwritten public offering of shares Oct. 5 on NASDAQ. It sold all of the 4.6 million shares of common stock it made available at $15 per share, the target price it set. The Shanghai-based firm said it intends to use the proceeds for general corporate purposes, including expanding its Shining retail operations and product lines and acquiring additional retail outlets. China-Biotics' products are available in pharmacies and supermarkets in Shanghai, Jiangsu and Zhejiang

You may also be interested in...

Sales & Earnings In Brief

Herbalife sales hit by currency exchange: Fourth-quarter net sales grow 23 percent to $630.9 million, though the effects of foreign currency fluctuation trim Herbalife's full-year sales 1.5 percent to $2.32 billion. The multilevel marketer of nutritional and weight-management products reported dramatic quarterly gains in net sales in the Asia Pacific region - up 56.2 percent to $151.5 million - and in South and Central America - up 34 percent to $113.2 million. Sales were flat or down in Mexico - affected by a value-added tax and distribution challenges - and in China, where sales leaders still are implementing the daily consumption model, Herbalife executives said Feb. 24. The Los Angeles firm said net income for the October-December period jumped 65.4 percent to $55.7 million, but dipped 8.1 percent to $203.3 million for the full year. Herbalife introduced more than 60 new or reformulated products across 72 countries during the year, CEO Michael Johnson said. The company projects net sales growth of 12.5 percent to 13.5 percent for its fiscal 2010 first quarter, and growth between 8.5 percent and 9.5 percent for the year

Warning Letter Close-Outs – March 2020

The US FDA released five device-related close-out letters in March.

Medicines Must Be Designated As Priority Items, Says IGBA

Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts